Maximum Dose of Allopurinol
The FDA-approved maximum dose of allopurinol is 800 mg per day in adults with normal renal function. 1
FDA-Approved Dosing Parameters
The maximum recommended dose is 800 mg per day, with initiation at 100 mg daily and weekly increases of 100 mg until serum uric acid falls below 6 mg/dL. 1
The FDA label explicitly states that dose escalation should continue "without exceeding the maximum recommended dose (800 mg per day)." 1
Contemporary Guideline Recommendations Align with FDA Maximum
The American College of Rheumatology (ACR) 2020 guidelines endorse titration up to the FDA-approved maximum of 800 mg daily when needed to achieve target serum urate levels below 6 mg/dL. 2
More than 50% of gout patients fail to reach target serum urate with doses ≤300 mg daily, making higher-dose titration essential for adequate disease control. 2, 3
Each 100 mg increment of allopurinol lowers serum urate by approximately 1 mg/dL, meaning patients starting at 8 mg/dL typically require 300–400 mg daily to reach target. 2
Titration Protocol to Maximum Dose
Start at 100 mg daily (or 50 mg daily if eGFR <30 mL/min) and increase by 100 mg increments every 2–5 weeks based on serum urate monitoring. 2, 3
Continue dose escalation until serum urate falls below 6 mg/dL (or below 5 mg/dL for severe tophaceous gout), even if this requires doses approaching 800 mg daily. 2, 3
Never cap the dose at 300 mg based on outdated renal-dosing algorithms; the ACR explicitly rejects these non-evidence-based restrictions. 2, 3
Mandatory Flare Prophylaxis During Titration
Initiate colchicine 0.5–1 mg daily (or NSAID with gastro-protection, or prednisone 5–10 mg daily) immediately when starting or increasing allopurinol, because rapid urate reduction precipitates acute gout attacks. 2, 1
Continue prophylaxis for at least 3–6 months after dose escalation, extending duration if flares persist. 2
The FDA label mandates that "maintenance doses of colchicine generally should be given prophylactically when allopurinol tablets are begun." 1
Dosing in Renal Impairment
The 800 mg maximum applies to patients with normal renal function; those with severe renal impairment (eGFR <30 mL/min) should start at 50 mg daily but may still be titrated above 300 mg with careful monitoring. 2, 4, 3
Modern ACR guidelines support dose titration above 300 mg even in chronic kidney disease stage ≥3 when close monitoring for hypersensitivity is performed, rejecting outdated renal-based dosing caps. 2, 3
In severely impaired renal function, the FDA label notes that "a dose of 100 mg per day or 300 mg twice a week, or perhaps less, may be sufficient," but this reflects conservative guidance that predates current treat-to-target strategies. 1
Safety Monitoring at Higher Doses
Monitor for allopurinol hypersensitivity syndrome (rash, pruritus, fever, eosinophilia, elevated liver enzymes) during the first 3–6 months, when risk is highest. 2, 4
Consider HLA-B*58:01 genetic testing before initiation in Korean patients with CKD stage ≥3, and in Han Chinese or Thai patients regardless of renal function. 2, 3
Check serum urate every 2–4 weeks during titration, then every 6 months once target is stable. 2, 3
Critical Pitfalls to Avoid
Do not accept a fixed 300 mg dose without titration—this leaves >50% of patients undertreated and at risk for ongoing flares, joint damage, and tophus formation. 2, 3
Do not increase dose without concurrent flare prophylaxis, as this markedly increases acute attack risk and reduces adherence. 2, 1
Do not apply outdated creatinine-clearance-based dosing caps that limit allopurinol to 100–200 mg in moderate renal impairment; these are non-evidence-based and impede adequate urate control. 2, 3